Search Result
Results for "
β-sheets
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P10294
-
|
|
Amyloid-β
|
Others
|
|
Oligopeptide P11-4 is an α-peptide that can be self-assembled into β-sheet amyloids with a hydrogel appearance at low pH. Oligopeptide P11-4 can be used in biomimetic mineralization, enamel regeneration and oral care agent .
|
-
-
- HY-122958
-
|
|
α-synuclein
|
Neurological Disease
|
|
Peucedanocoumarin III is an α-synuclein fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease .
|
-
-
- HY-P3688A
-
|
Aβ (1-38) TFA; Aβ38 TFA
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid (1-38) (Aβ (1-38)) TFA is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) TFA interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38)TFA reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
|
-
-
- HY-137557
-
|
APN1607; PM-PBB3
|
Tau Protein
|
Neurological Disease
|
|
Florzolotau (APN1607) is a positron emission tomography (PET) ligand that can be used for the detection of Alzheimer's disease (AD) and other tau proteinopathies. Its binding sites are located in the β-sheet of paired helical filaments (PHFs) and straight filaments (SFs) of tau protein, as well as in the C-shaped cavity of SFs. In addition, APN-1607 binds to intraneuronal inclusions in Alzheimer's disease (AD), primary age-related tauopathy (PART) and posterior cortical atrophy (PCA). Florzolotau shows promise for PET imaging studies of neurological disorders, particularly tau proteinopathies .
|
-
-
- HY-P1047
-
|
[Pro18, Asp21] β-Amyloid (17-21)
|
Amyloid-β
|
Neurological Disease
|
|
β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.
|
-
-
- HY-P5905
-
|
Citrullinated Aβ (1-42); Citrullinated Aβ42
|
Amyloid-β
|
Neurological Disease
|
|
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .
|
-
-
- HY-N8671
-
|
|
Amyloid-β
Apoptosis
Reactive Oxygen Species (ROS)
SARS-CoV
|
Infection
Neurological Disease
|
|
Withanoside V is a blood-brain barrier-permeable withanolide derivative . Withanoside V binds strongly to Sudlow I (domain IIA) of human serum albumin (HSA) to form a stable complex and alter the secondary structure of albumin, thereby increasing helix content and reducing β-sheet and random coil. Withanoside V binds to Aβ (1-42) to block the interaction between monomers and subsequent aggregation. Withanoside V inhibits the viability of neuroblastoma cells, reduces the number of apoptotic cells induced by Aβ (1-42), and decreases ROS production. Withanoside V inhibits SARS-CoV-2 Mpro. Withanoside V can be used for research on Alzheimer's disease and coronavirus disease 2019 .
|
-
-
- HY-114508
-
|
3-Phenylpropiophenone; β-Phenylpropiophenone
|
Amyloid-β
|
Neurological Disease
|
|
Dihydrochalcone (3-Phenylpropiophenone) is a Aβ aggregation inhibitor. Dihydrochalcone destabilizes Aβ17-42 protofibrils by disrupting the β-sheet of β1 region. Dihydrochalcone destabilizes both U-shaped Aβ40/Aβ42 protofibrils and S-shaped Aβ42 protofibrils by binding to the protofibril cavity. Dihydrochalcone is the main component of daemonorops draco tree .
|
-
-
- HY-141661
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Aβ/tau aggregation-IN-1 is a potent Aβ1-42 β-sheets formation and tau aggregation inhibitor. The KD values of Aβ/tau aggregation-IN-1 with Aβ1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier .
|
-
-
- HY-P10578
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease .
|
-
-
- HY-W835959
-
|
|
Tau Protein
|
Neurological Disease
|
|
ACI-3024 is an an orally active and highly selective Tau protein aggregation inhibitor. ACI-3024 decrease the β-sheet content and seeding properties of pathological Tau from different Tauopathies, leading to a significant rescue of the Tau-induced neurodegeneration and neuroinflammation in a cellular model. ACI-3024 is promising for research of neurodegenerative diseases .
|
-
-
- HY-P10701
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
Cancer
|
|
Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology .
|
-
-
- HY-P11309
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
QL6 peptide is a self-assembling peptide. QL6 peptide can self-assembles into β-sheets bridging the cavity at neutral pH and improves the inhibitory environment by reducing inflammation and tissue scaring. QL6 peptide can be used for synthesis nanofiber scaffolds for spinal cord injuries (SCI) research .
|
-
-
- HY-P3688
-
|
Aβ (1-38); Aβ38
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid (1-38) (Aβ (1-38)) is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38) reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
|
-
-
- HY-P5917A
-
|
Vaejovis mexicanus peptide 24 TFA
|
Potassium Channel
|
Inflammation/Immunology
Cancer
|
|
Vm24-toxin (Vaejovis mexicanus peptide 24) TFA, a 36-residue peptide, is a potent and selective Kv1.3 blocker with a Kd of ~3 pM in lymphocytes. Vm24-toxin TFA shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin TFA folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin TFA attenuates the CD4 + effector memory T cell response to T cell receptor (TCR) stimulation .
|
-
-
- HY-P4370
-
|
|
Bacterial
Fungal
|
Infection
|
|
Hepcidin-20 (human) is a histidine-containing, cysteine-rich, β-sheet structured peptide. Hepcidin-20 (human) shows antifungal activity. Hepcidin-20 (human) inhibits biofilm formation and bacterial cell metabolism of polysaccharide intercellular adhesin (PIA)-positive and PIA-negative strains .
|
-
-
- HY-P5906
-
|
Citrullinated Aβ (1-40); Citrullinated Aβ40
|
Amyloid-β
|
Neurological Disease
|
|
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .
|
-
-
- HY-P10534
-
|
|
Prion Protein
|
Infection
Neurological Disease
|
|
CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .
|
-
-
- HY-P4873
-
|
|
Amylin Receptor
|
Neurological Disease
|
|
Amylin (20-29) (human) is the fragment of human islet amyloid polypeptide (hIAPP) or Amylin. Amylin is a 37-residue hormone. Amylin (20-29) (human) is responsible for the amyloidogenic propensities of the full length protein. Amylin (20-29) (human) can be transformed into its corresponding peptoid and retropeptoid sequences, to obtain beta-sheet breaker peptides as amyloid inhibitors .
|
-
-
- HY-114884
-
|
|
Amyloid-β
|
Neurological Disease
|
|
RS-0406 is a beta-sheet breaker targeting Amyloid-β. RS-0406 can inhibits Aβ(1-42) fibrillogenesis and protect against Aβ(1-42)-induced cytotoxicity in primary hippocampal neurons. RS-0406 can be used for the research of neurological disease, such as Alzheimer's disease (AD) .
|
-
-
- HY-149509
-
|
|
α-synuclein
|
Neurological Disease
|
|
α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .
|
-
-
- HY-13325
-
|
|
Drug Derivative
Amyloid-β
|
Neurological Disease
|
|
Aβ aggregation modulator-1 is a stimulator of amyloid-β (Aβ) fibrillogenesis. Aβ aggregation modulator-1 binds hydrophobic residues in Aβ peptides and stabilizes β-sheet-rich protofibrils and fibrils. Aβ aggregation modulator-1 accelerates Aβ polymerization and reduces concentrations of small, toxic Aβ oligomers in heterogeneous aggregation reactions. Aβ aggregation modulator-1 suppresses long-term potentiation (LTP) inhibition by Aβ oligomers in hippocampal brain slices. Aβ aggregation modulator-1 can be used for the study of Alzheimer's disease (AD) .
|
-
-
- HY-P5917
-
|
Vaejovis mexicanus peptide 24
|
Potassium Channel
|
Inflammation/Immunology
Cancer
|
|
Vm24-toxin (Vaejovis mexicanus peptide 24), a 36-residue peptide, is a potent and selective Kv1.3 blocker with a Kd of ~3 pM in lymphocytes. Vm24-toxin shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin attenuates the CD4 + effector memory T cell response to T cell receptor (TCR) stimulation .
|
-
-
- HY-161658
-
|
|
Amyloid-β
|
Neurological Disease
|
|
N-Caffeoyldopamine (Compound 6i) is an amyloid-beta aggregation inhibitor. N-Caffeoyldopamine can inhibit Aβ aggregation to form nano-rod-like structures, thereby preventing β-sheet formation. N-Caffeoyldopamine can be used for Alzheimer's disease research .
|
-
-
- HY-D3430
-
|
|
Fluorescent Dye
Amyloid-β
|
Neurological Disease
|
|
PTPA-QM is a low-cytotoxicity Aβ protein probe that can be used for live-cell imaging and tissue section staining (Lys. Ex/Em = 385/615 nm). PTPA-QM can intercalate into the β-sheet layered structure of β-amyloid fibrils, form intermolecular interactions with amino acid residues, restrict intramolecular rotation and trigger fluorescence activation for imaging purposes. PTPA-QM is applicable to Alzheimer's disease-related research. Maximum excitation/emission wavelength: 448/605 nm .
|
-
-
- HY-114613
-
|
|
Amyloid-β
α-synuclein
CGRP Receptor
Amylin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
D-Trp-Aib is a dipeptide and amyloid-β inhibitor with a Kd of 29.6 nM. D-Trp-Aib triggers formation of non-toxic, non-β-sheet, amorphous amyloid β clusters from misfolded amyloid β monomers and toxic amyloid β oligomers, and reduces toxic amyloid β1-42 deposits. D-Trp-Aib inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin. D-Trp-Aib can be used for the research of Alzheimer's disease .
|
-
-
- HY-137557A
-
|
(E/Z)-APN1607; (E/Z)-PM-PBB3
|
Tau Protein
|
Neurological Disease
|
|
(E/Z)-Florzolotau ((E/Z)-APN1607) is a mixed configuration or unspecified configuration of Florzolotau (HY-137557). Florzolotau (APN1607) is a positron emission tomography (PET) ligand that can be used for the detection of Alzheimer's disease (AD) and other tau proteinopathies. Its binding sites are located in the β-sheet of paired helical filaments (PHFs) and straight filaments (SFs) of tau protein, as well as in the C-shaped cavity of SFs. In addition, APN-1607 binds to intraneuronal inclusions in Alzheimer's disease (AD), primary age-related tauopathy (PART) and posterior cortical atrophy (PCA). Florzolotau shows promise for PET imaging studies of neurological disorders, particularly tau proteinopathies .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D3430
-
|
|
Fluorescent Dyes
|
|
PTPA-QM is a low-cytotoxicity Aβ protein probe that can be used for live-cell imaging and tissue section staining (Lys. Ex/Em = 385/615 nm). PTPA-QM can intercalate into the β-sheet layered structure of β-amyloid fibrils, form intermolecular interactions with amino acid residues, restrict intramolecular rotation and trigger fluorescence activation for imaging purposes. PTPA-QM is applicable to Alzheimer's disease-related research. Maximum excitation/emission wavelength: 448/605 nm .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10294
-
|
|
Amyloid-β
|
Others
|
|
Oligopeptide P11-4 is an α-peptide that can be self-assembled into β-sheet amyloids with a hydrogel appearance at low pH. Oligopeptide P11-4 can be used in biomimetic mineralization, enamel regeneration and oral care agent .
|
-
- HY-P3688A
-
|
Aβ (1-38) TFA; Aβ38 TFA
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid (1-38) (Aβ (1-38)) TFA is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) TFA interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38)TFA reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
|
-
- HY-P1047
-
|
[Pro18, Asp21] β-Amyloid (17-21)
|
Amyloid-β
|
Neurological Disease
|
|
β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.
|
-
- HY-P5905
-
|
Citrullinated Aβ (1-42); Citrullinated Aβ42
|
Amyloid-β
|
Neurological Disease
|
|
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .
|
-
- HY-P10578
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease .
|
-
- HY-P10701
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
Cancer
|
|
Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology .
|
-
- HY-P11309
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
QL6 peptide is a self-assembling peptide. QL6 peptide can self-assembles into β-sheets bridging the cavity at neutral pH and improves the inhibitory environment by reducing inflammation and tissue scaring. QL6 peptide can be used for synthesis nanofiber scaffolds for spinal cord injuries (SCI) research .
|
-
- HY-P3688
-
|
Aβ (1-38); Aβ38
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid (1-38) (Aβ (1-38)) is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38) reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
|
-
- HY-P5917A
-
|
Vaejovis mexicanus peptide 24 TFA
|
Potassium Channel
|
Inflammation/Immunology
Cancer
|
|
Vm24-toxin (Vaejovis mexicanus peptide 24) TFA, a 36-residue peptide, is a potent and selective Kv1.3 blocker with a Kd of ~3 pM in lymphocytes. Vm24-toxin TFA shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin TFA folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin TFA attenuates the CD4 + effector memory T cell response to T cell receptor (TCR) stimulation .
|
-
- HY-P4370
-
|
|
Bacterial
Fungal
|
Infection
|
|
Hepcidin-20 (human) is a histidine-containing, cysteine-rich, β-sheet structured peptide. Hepcidin-20 (human) shows antifungal activity. Hepcidin-20 (human) inhibits biofilm formation and bacterial cell metabolism of polysaccharide intercellular adhesin (PIA)-positive and PIA-negative strains .
|
-
- HY-P10155
-
|
|
Peptides
|
Others
|
|
VT5 is a β-sheet amphipathic peptide consisting of 26 amino acids. VT5 has the ability to form β-sheets for cellular internalization .
|
-
- HY-P5906
-
|
Citrullinated Aβ (1-40); Citrullinated Aβ40
|
Amyloid-β
|
Neurological Disease
|
|
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .
|
-
- HY-P11231
-
|
FUS(364-369)-TAT
|
Peptides
|
Cancer
|
|
β4-TAT is a kind of β-sheet peptide foldamer. β4-TAT is composed of two parts: the β4 sequence (derived from the β-sheet fragment of the RRM domain of fused in sarcoma (FUS)) and the TAT sequence (a nuclear localization signal peptide that helps the entire peptide penetrate the nuclear membrane). β4-TAT influences FUS aggregation by targeting its RNA recognition motifs (RRM). β4-TAT effectively induces FUS aggregation within cells, leading to the death of cancer cells. β4-TAT can be used for the study of FUS .
|
-
- HY-P5515
-
|
|
Peptides
|
Others
|
|
F(N-Me)GA(N-Me)IL is a biological active peptide. (Double N-methylated derivatives of amyloidogenic and cytotoxic partial IAPP sequence were found to be devoid of β-sheet structure, amyloidogenicity and cytotoxicity, The derivatives were able to interact with the native sequences and inhibit amyloid formation)
|
-
- HY-P5967
-
|
|
Peptides
|
Neurological Disease
|
|
Acetly-β Amyloid (15-20), Amide is a peptides fragment. Acetly-β Amyloid (15-20), Amide inhibits the β-sheet formation and stabilizes structure of Aβ (1–40) peptide. Acetly-β Amyloid (15-20), Amide can be used in study Alzheimer’s disease .
|
-
- HY-P10534
-
|
|
Prion Protein
|
Infection
Neurological Disease
|
|
CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .
|
-
- HY-P4873
-
|
|
Amylin Receptor
|
Neurological Disease
|
|
Amylin (20-29) (human) is the fragment of human islet amyloid polypeptide (hIAPP) or Amylin. Amylin is a 37-residue hormone. Amylin (20-29) (human) is responsible for the amyloidogenic propensities of the full length protein. Amylin (20-29) (human) can be transformed into its corresponding peptoid and retropeptoid sequences, to obtain beta-sheet breaker peptides as amyloid inhibitors .
|
-
- HY-P5340
-
|
|
Peptides
|
Others
|
|
Amyloid-Forming peptide GNNQQNY is a biological active peptide. (This is a heptapeptide from the N-terminal prion-determining domain of the yeast protein Sup35 that forms amyloid fibrils. The availability of its detailed atomic oligomeric structure makes it a good model for studying the early stage of aggregation. The GNNQQNY dimer forms three stable sheet structures. in-register parallel, off-register parallel, and anti-parallel. The in-register parallel dimer, which is close to the amyloid beta-sheet structure, has few interpeptide hydrogen bonds, making hydrophobic interactions more important and increasing the conformational entropy compared to the anti-parallel sheet.)
|
-
- HY-P5917
-
|
Vaejovis mexicanus peptide 24
|
Potassium Channel
|
Inflammation/Immunology
Cancer
|
|
Vm24-toxin (Vaejovis mexicanus peptide 24), a 36-residue peptide, is a potent and selective Kv1.3 blocker with a Kd of ~3 pM in lymphocytes. Vm24-toxin shows >1500-fold affinity for Kv1.3 over other assayed potassium channels. Vm24-toxin folds into a distorted cystine-stabilized α/β motif consisting of a single-turn α-helix and a three-stranded antiparallel β-sheet, stabilized by four disulfide bridges. Vm24-toxin attenuates the CD4 + effector memory T cell response to T cell receptor (TCR) stimulation .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-122958
-
-
-
- HY-N8671
-
|
|
Structural Classification
Withania somnifera
Solanaceae
Plants
Steroids
Source Classification
|
Amyloid-β
Apoptosis
Reactive Oxygen Species (ROS)
SARS-CoV
|
|
Withanoside V is a blood-brain barrier-permeable withanolide derivative . Withanoside V binds strongly to Sudlow I (domain IIA) of human serum albumin (HSA) to form a stable complex and alter the secondary structure of albumin, thereby increasing helix content and reducing β-sheet and random coil. Withanoside V binds to Aβ (1-42) to block the interaction between monomers and subsequent aggregation. Withanoside V inhibits the viability of neuroblastoma cells, reduces the number of apoptotic cells induced by Aβ (1-42), and decreases ROS production. Withanoside V inhibits SARS-CoV-2 Mpro. Withanoside V can be used for research on Alzheimer's disease and coronavirus disease 2019 .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: